ReviewCNS drug reviews2003
The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review.
Review in CNS drug reviews, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.Molecular psychiatry · 2010Pooled it
- Cortisol as a Target for Treating Mental Disorders: A Promising Avenue for Therapy.Mini reviews in medicinal chemistry · 2024Review
- Preterm Birth and Corticotrophin-Releasing Hormone as a Placental Clock.Endocrinology · 2022Review
- A multiscale approach for bridging the gap between potency, efficacy, and safety of small molecules directed at membrane proteins.Scientific reports · 2021Article
- Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer's disease and stress disorders.Translational psychiatry · 2019Review
- Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract.Current molecular pharmacology · 2018Review
- Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis.PloS one · 2018Article
- Prevention of alcohol-heightened aggression by CRF-R1 antagonists in mice: critical role for DRN-PFC serotonin pathway.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Article
- Controversies about a common etiology for eating and mood disorders.Frontiers in psychology · 2014Review
- Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use.Frontiers in neuroscience · 2014Review
- Differential effect of orexin-1 and CRF-1 antagonism on stress circuits: a fMRI study in the rat with the pharmacological stressor Yohimbine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Article
- The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression.CNS drugs · 2011Review
- Estradiol effects on behavior and serum oxytocin are modified by social status and polymorphisms in the serotonin transporter gene in female rhesus monkeys.Hormones and behavior · 2011Article
- Pharmacogenetics of antidepressant response.Journal of psychiatry & neuroscience : JPN · 2011Review
- Restraint stress-induced reduction in prepulse inhibition in Brown Norway rats: role of the CRF2 receptor.Neuropharmacology · 2011Article
- Pharmacogenetics of antidepressants.Frontiers in pharmacology · 2011Article
- Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.Pharmacology & therapeutics · 2010Review
- Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes.Addiction biology · 2010Review
- Hippocampal changes associated with early-life adversity and vulnerability to depression.Biological psychiatry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since CRH has been shown to mediate stress-induced physiological and behavioral changes, it has been hypothesized that CRH receptor antagonists may have therapeutic potential in disorders that involve excessive CRH activity. CP-154,526 and its close analog antalarmin are potent, brain-penetrable, selective nonpeptide CRH1 receptor antagonists that were discovered in an effort to develop compounds with efficacy in CNS disorders precipitated by stress. Since its discovery many investigators have used CP-154,526 as a tool to study the pharmacology of CRH and its receptors and to evaluate its therapeutic potential in a variety of CNS and peripheral disorders. Systemically-administered CP-154,526 has been demonstrated to antagonize CRH- and stress-induced neuroendocrine, neurochemical, electrophysiological, and behavioral effects. These findings support the hypothesis that CRH1 receptor antagonists may have therapeutic utility in a number of neuropsychiatric disorders. CP-154,526, as well as other CRH1 receptor antagonists that have since been discovered, have also shown activity in several preclinical models of anxiety, depression, and substance abuse, while having little effect on locomotor activity and motor function. Although these effects are on occasion inconsistent among different laboratories, clinical evaluation of CRH1 antagonists appears justified on the basis of these and clinical data implicating the involvement of CRH in several CNS disorders. The effects of CRH1 antagonists on cognition, neurodegeneration, inflammation, and the gastrointestinal system have not been as extensively characterized and additional studies will be necessary to evaluate their therapeutic potential in these areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.